Prostatype Genomics AB (OSTO:PROGEN) NonCurrent Deferred Liabilities: kr0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
23 GF Score
Price kr0.24
GF Value kr0.04
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB NonCurrent Deferred Liabilities?

Prostatype Genomics AB OSTO:PROGEN +62.20% 23 NonCurrent Deferred Liabilities is kr0.00 Mil as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 23/100 and a GF Value™ of kr0.04 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Prostatype Genomics AB's non-current deferred liabilities for the quarter that ended in Dec. 2025 was kr0.00 Mil.

Prostatype Genomics AB NonCurrent Deferred Liabilities Related Terms

Prostatype Genomics AB NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB NonCurrent Deferred Liabilities Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:PROGEN
23GF Score
Prostatype Genomics AB OSTO:PROGEN
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of kr0.00 Mil mean?
Prostatype Genomics AB (OSTO:PROGEN) has a NonCurrent Deferred Liabilities of kr0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's NonCurrent Deferred Liabilities too high?
Prostatype Genomics AB's current NonCurrent Deferred Liabilities is kr0.00 Mil. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's NonCurrent Deferred Liabilities compare to TMO and DHR?
Prostatype Genomics AB's NonCurrent Deferred Liabilities of kr0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Liabilities depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current NonCurrent Deferred Liabilities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.24 — trading 490% above its estimated fair value. The current NonCurrent Deferred Liabilities is kr0.00 Mil. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current NonCurrent Deferred Liabilities is kr0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.24 is trading 490% above its estimated GF Value™ of kr0.04. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • NonCurrent Deferred Liabilities: kr0.00 Mil
  • GF Value™: kr0.04 vs. price of kr0.24 (490% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score

Get the complete analysis for OSTO:PROGEN

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.24
Price
kr0.04
GF Value